Instructions: In this task, you are given text for US Congressional and California state bills, your task is to generate a summary for this bill.
Input: SECTION 1. SHORT TITLE.

This Act may be cited as the ''Lung Cancer Mortality Reduction Act
of 2008''.

SEC. 2. FINDINGS.

Congress makes the following findings:
(1) Lung cancer is the leading cause of cancer death for
both men and women, accounting for 28 percent of all cancer
deaths.
(2) Lung cancer kills more people annually than breast
cancer, prostate cancer, colon cancer, liver cancer, melanoma,
and kidney cancer combined.
(3) Since the National Cancer Act of 1971 (Public Law 92-
218; 85 Stat. 778), coordinated and comprehensive research has
raised the 5-year survival rates for breast cancer to 88
percent, for prostate cancer to 99 percent, and for colon
cancer to 64 percent.
(4) However, the 5-year survival rate for lung cancer is
still only 15 percent and a similar coordinated and
comprehensive research effort is required to achieve increases
in lung cancer survivability rates.
(5) Sixty percent of lung cancer cases are now diagnosed as
nonsmokers or former smokers.
(6) Two-thirds of nonsmokers diagnosed with lung cancer are
women.
(7) Certain minority populations, such as African-American
males, have disproportionately high rates of lung cancer
incidence and mortality, notwithstanding their similar smoking
rate.
(8) Members of the baby boomer generation are entering
their sixties, the most common age at which people develop lung
cancer.
(9) Tobacco addiction and exposure to other lung cancer
carcinogens such as Agent Orange and other herbicides and
battlefield emissions are serious problems among military
personnel and war veterans.
(10) Significant and rapid improvements in lung cancer
mortality can be expected through greater use and access to
lung cancer screening tests for at-risk individuals.
(11) Additional strategies are necessary to further enhance
the existing tests and therapies available to diagnose and
treat lung cancer in the future.
(12) The August 2001 Report of the Lung Cancer Progress
Review Group of the National Cancer Institute stated that
funding for lung cancer research was ''far below the levels
characterized for other common malignancies and far out of
proportion to its massive health impact''.
(13) The Report of the Lung Cancer Progress Review Group
identified as its ''highest priority'' the creation of
integrated, multidisciplinary, multi-institutional research
consortia organized around the problem of lung cancer rather
than around specific research disciplines.
(14) The United States must enhance its response to the
issues raised in the Report of the Lung Cancer Progress Review
Group, and this can be accomplished through the establishment
of a coordinated effort designed to reduce the lung cancer
mortality rate by 50 percent by 2015 and targeted funding to
support this coordinated effort.

SEC. 3. SENSE OF THE SENATE CONCERNING INVESTMENT IN LUNG CANCER
RESEARCH.

It is the sense of the Senate that--
(1) lung cancer mortality reduction should be made a
national public health priority; and
(2) a comprehensive mortality reduction program coordinated
by the Secretary of Health and Human Service is justified and
necessary to adequately address and reduce lung cancer
mortality.

SEC. 4. LUNG CANCER MORTALITY REDUCTION PROGRAM.

(a) In General.--Subpart 1 of part C of title IV of the Public
Health Service Act (42 U.S.C. 285 et seq.) is amended by adding at the
end the following:

''SEC. 417E. LUNG CANCER MORTALITY REDUCTION PROGRAM.

''(a) In General.--Not later than 6 months after the date of
enactment of the Lung Cancer Mortality Reduction Act of 2008, the
Secretary, in consultation with the Secretary of Defense, the Secretary
of Veterans Affairs, the Director of the National Institutes of Health,
the Director of the Centers for Disease Control and Prevention, the
Administrator of the Food and Drug Administration, the Director of the
Centers for Medicare & Medicaid Services, the Director of the National
Center on Minority Health and Health Disparities, and other members of
the Lung Cancer Advisory Board established under section 6 of the Lung
Cancer Mortality Reduction Act of 2008, shall implement a comprehensive
program to achieve a 50 percent reduction in the mortality rate of lung
cancer by 2015.
''(b) Requirements.--The program implemented under subsection (a)
shall include at least the following:
''(1) With respect to the National Institutes of Health--
''(A) a strategic review and prioritization by the
National Cancer Institute of research grants to achieve
the goal of the program in reducing lung cancer
mortality;
''(B) the provision of funds to enable the Airway
Biology and Disease Branch of the National Heart, Lung
and Blood Institute to expand its research programs to
include predispositions to lung cancer, the
interrelationship between lung cancer and other
pulmonary and cardiac disease, and the diagnosis and
treatment of these interrelationships;
''(C) the provision of funds to enable the National
Institute of Biomedical Imaging and Bioengineering to
expand its Quantum Grant Program and Image-Guided
Interventions programs to expedite the development of
computer assisted diagnostic, surgical, treatment and
drug testing innovations to reduce lung cancer
mortality; and
''(D) the provision of funds to enable the National
Institute for Environmental Health Sciences to
implement research programs relative to lung cancer
incidence.
''(2) With respect to the Food and Drug Administration--
''(A) the establishment of a lung cancer mortality
reduction drug program under subtitle G of chapter V of
the Federal Food, Drug, and Cosmetic Act; and
''(B) compassionate access activities under section
561 of the Federal Food, Drug, and Cosmetic Act (21
U.S.C. 360bbb).
''(3) With respect to the Centers for Disease Control and
Prevention, the establishment of a lung cancer mortality
reduction program under section 1511.
''(4) With respect to the Agency for Healthcare Research
and Quality, the conduct of a biannual review of lung cancer
screening, diagnostic and treatment protocols, and the issuance
of updated guidelines.
''(5) The cooperation and coordination of all minority and
health disparity programs within the Department of Health and
Human Services to ensure that all aspects of the Lung Cancer
Mortality Reduction Program adequately address the burden of
lung cancer on minority and rural populations.
''(6) The cooperation and coordination of all tobacco
control and cessation programs within agencies of the
Department of Health and Human Services to achieve the goals of
the Lung Cancer Mortality Reduction Program with particular
emphasis on the coordination of drug and other cessation
treatments with early detection protocols.
''(c) Authorization of Appropriations.--There is authorized to be
appropriated to carry out this section--
''(1) $25,000,000 for fiscal year 2009 for the activities
described in subsection (b)(1)(B), and such sums as may be
necessary for each of fiscal years 2010 through 2013;
''(2) $25,000,000 for fiscal year 2009 for the activities
described in subsection (b)(1)(C), and such sums as may be
necessary for each of fiscal years 2010 through 2013;
''(3) $10,000,000 for fiscal year 2009 for the activities
described in subsection (b)(1)(D), and such sums as may be
necessary for each of fiscal years 2010 through 2013; and
''(4) $15,000,000 for fiscal year 2009 for the activities
described in subsection (b)(3), and such sums as may be
necessary for each of fiscal years 2010 through 2013.''.
(b) Food, Drug, and Cosmetic Act.--Chapter V of the Federal Food,
Drug, and Cosmetic Act (21 U.S.C. 351 et seq.) is amended by adding at
the end the following:

''Subchapter G--Lung Cancer Mortality Reduction Programs

''SEC. 581. LUNG CANCER MORTALITY REDUCTION PROGRAM.

''(a) In General.--The Secretary shall implement a program to
provide incentives of the type provided for in subchapter B of this
chapter for the development of chemoprevention drugs for precancerous
conditions of the lung, drugs for targeted therapeutic treatments and
vaccines for lung cancer, and new agents to curtail or prevent nicotine
addiction. The Secretary shall model the program implemented under this
section on the program provided for under subchapter B of this chapter
with respect certain drugs.
''(b) Application of Provisions.--The Secretary shall apply the
provisions of subchapter B of this chapter to drugs, biological
products, and devices for the prevention or treatment of lung cancer,
including drugs, biological products, and devices for chemoprevention
of precancerous conditions of the lungs, vaccination against the
development of lung cancer and therapeutic treatment for lung cancer.
''(c) Board.--The Board established under section 6 of the Lung
Cancer Mortality Reduction Act of 2008 shall monitor the program
implemented under this section.''.
(c) Access to Unapproved Therapies.--Section 561(e) of the Federal
Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb(e)) is amended by
inserting before the period the following: ''and shall include
providing compassionate access to drugs, biological products, and
devices under the program under section 581, with substantial
consideration being given to whether the totality of information
available to the Secretary regarding the safety and effectiveness of an
investigational drug, as compared to the risk of morbidity and death
from the disease, indicates that a patient may obtain more benefit than
risk if treated with the drug, biological product, or device.''.
(d) CDC.--Title XV of the Public Health Service Act (42 U.S.C. 300k
et seq.) is amended by adding at the end the following:

''SEC. 1511. LUNG CANCER MORTALITY REDUCTION PROGRAM.

''(a) In General.--The Secretary shall establish and implement an
early disease research and management program targeted at the high
incidence and mortality rates among minority and low-income
populations.
''(b) Authorization of Appropriations.--There is authorized to be
appropriated, such sums as may be necessary to carry out this
section.''.

SEC. 5. DEPARTMENT OF DEFENSE AND THE DEPARTMENT OF VETERANS AFFAIRS.

The Secretary of Defense and the Secretary of Veterans Affairs
shall coordinate with the Secretary of Health and Human Services--
(1) in the development of the Lung Cancer Mortality
Reduction Program under section 417E;
(2) in the implementation within the Department of Defense
and the Department of Veterans Affairs of an early detection
and disease management research program for military personnel
and veterans whose smoking history and exposure to carcinogens
during active duty service has increased their risk for lung
cancer; and
(3) in the implementation of coordinated care programs for
military personnel and veterans diagnosed with lung cancer.

SEC. 6. LUNG CANCER ADVISORY BOARD.

(a) In General.--The Secretary of Health and Human Services shall
establish a Lung Cancer Advisory Board (referred to in this section as
the ''Board'') to monitor the programs established under this Act (and
the amendments made by this Act), provide annual reports to Congress
concerning benchmarks, expenditures, lung cancer statistics, and the
public health impact of such programs.
(b) Composition.--The Board shall be composed of--
(1) the Secretary of Health and Human Services;
(2) the Secretary of Defense;
(3) the Secretary of Veterans Affairs; and
(4) two representatives each from the fields of clinical
medicine focused on lung cancer, lung cancer research, imaging,
drug development, and lung cancer advocacy, to be appointed by
the Secretary of Health and Human Services.

SEC. 7. AUTHORIZATION OF APPROPRIATIONS.

For the purpose of carrying out the programs under this Act (and
the amendments made by this Act), there is authorized to be
appropriated such sums as may be necessary for each of fiscal years
2009 through 2013.
Output:
Lung Cancer Mortality Reduction Act of 2008 - Amends the Public Health Service Act to require the Secretary of Health and Human Services (the Secretary) to implement a comprehensive program to achieve a 50% reduction in the mortality rate of lung cancer by 2015. Includes within such program: (1) a strategic review and prioritization of research grants; (2) an expansion of research programs, such as on predispositions to lung cancer; and (3) the expedited development of computer assisted diagnostic, surgical, treatment, and drug testing innovations.

Amends the Federal Food, Drug, and Cosmetic Act to require the Secretary to provide incentives for the development of chemoprevention drugs for precancerous conditions of the lung, drugs for targeted therapeutic treatments and vaccines for lung cancer, and new agents to curtail or prevent nicotine addiction.

Provides for compassionate access to drugs, biological products, and devices under the lung cancer mortality reduction program. Requires the Secretary to establish an early disease research and management program targeted at the high incidence and mortality rates among minority and low income populations.

Requires the Secretary of Defense and the Secretary of Veterans Affairs to coordinate with the Secretary in: (1) the development of the lung cancer mortality reduction program under this Act; (2) the implementation of an early detection and disease management research program for military personnel and veterans whose smoking history and exposure to carcinogens during active duty service has increased their risk for lung cancer; and (3) the implementation of coordinated care programs for military personnel and veterans diagnosed with lung cancer.

Requires the Secretary to establish a Lung Cancer Advisory Board to monitor the programs established under this Act.